

## 6. Surdosage en anticancéreux

Les surdosages en anticancéreux, notamment en pédiatrie font partie des 12 événements qui ne devraient jamais arriver d'après l'ANSM (*Never events*). Vous trouverez dans ce document les liens vers de la bibliographie et des outils concernant les surdosages en anticancéreux, en France et à l'étranger. Ce document est régulièrement remis à jour.

### 1. Problématique

#### France

**(1) Iatrogénie médicamenteuse liée à la prescription en chimiothérapie anticancéreuse. E.Schmit, GERPAC 2000.** Accessible sur :

[http://www.gerpac.eu/IMG/pdf/2000\\_09.pdf](http://www.gerpac.eu/IMG/pdf/2000_09.pdf)

#### Royaume Uni

**(2) Oral anticancer medicines: risks of incorrect dosing - Supporting information.**

Accessible sur :

<http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=60277&type=full&service=Attachment>

#### Etats-Unis

**(3) ISMP Alert 1998 - Urgent drug safety message: Medication errors with certain lipid-based drug products.** Accessible sur :

<http://www.ismp.org/newsletters/acutecare/articles/19980818.asp>

**(4) The New York Times, 2002 - Chemotherapy overdose for two children.** Accessible sur :

<http://www.nytimes.com/2002/08/02/us/national-briefing-health-and-science-chemotherapy-overdoses-for-2-children.html>

**(5) Flat-Fixed Dosing Versus Body Surface Area-Based Dosing of Anticancer Drugs in Adults: Does It Make a Difference?** Mathijssen et al., *Oncologist* 2007;12 :913-923. Accessible sur :

<http://theoncologist.alphamedpress.org/content/12/8/913.full.pdf+html>

## 2. Recommandations

### Royaume Uni

**(6) NHS 2008 : Oral anticancer medicines: risks of incorrect dosing - Rapid Response Report.** Accessible sur :

<http://www.nrls.npsa.nhs.uk/EasySiteWeb/getresource.axd?AssetID=60278&type=full&serviceType=Attachment>

## 3. Publications sur le sujet

**(7) Estimation du nombre et de la nature des interactions médicamenteuses concernant les médicaments anticancéreux.** Schwartz et al., Bull Cancer 2007;94:477-82

**(8) Potential of chemotherapy-herb interactions in adult cancer patients.** McCune et al., Support Care Cancer, 2004;12:454-62

**(9) Herbal remedies in the United States : potential adverse interactions with anticancer agents.** Sparreboom et al., J Clin Oncol 2004;22:2489-503

**(10) Improving European cooperation on medication errors.** Cheung et al., Lancet 2014;383:1209-10

**(11) Preventing vincristine sulfate medication errors.** Schulmeister, Oncol Nurs Forum 2004;31:E90-8

**(12) Cola beverage and delayed elimination of methotrexate,** Santucci et al., BCJP 2010; 70:762-4

**(13) Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors.** Santucci et al., Anticancer Res. 2010;30:3807-10

**(14) Life-threatening Torsades de pointes resulting from “natural” cancer treatment.** Chan et al., Clin Toxicol (Phila) 2009;47:592-4

**(15) Fatal cesium chloride toxicity after alternative cancer treatment.** Sessions et al., J Altern Complement Med 2013;19:973-5.

**(16) Use of uridine triacetate for the management of fluorouracil overdose.** McEvelly et al., Am J Health Syst Pharm 2011;68:1806-9.

**(17) SIMMEON-Prep study : SIMulation of Medication Errors in Oncology : prevention of antineoplastic preparation errors.** Sarfati et al., J Clin Pharm Ther 2014 doi:10.1111/jcpt.12225. [Epub ahead of print]

- (18) Maîtrise des erreurs de préparation des médicaments anticancéreux en unité centralisée : de l'épidémiologie à l'assurance qualité.** Martin et al., Bull Cancer 2004;91:972-6.
- (19) Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective.** Van Leeuwen et al., Lancet Oncol 2014;15:e315-26
- (20) Chemotherapy prescribing errors: an observational study on the role of information technology and computerized physician order entry systems.** Aita et al., BMC Health Serv res 2013;13:522
- (21) Does applying technology throughout the medication use process improve patient safety with antineoplastics?** Bubalo et al., J Oncol Pharm Pract 2014;20:445-60
- (22) Accidental overdose of intrathecal cytarabine in children.** Thienpravoon et al., Ann Pharmacother 2013;47:e24
- (23) Impact of robotic antineoplastic preparation on safety, workflow, and costs.** Seger et al., J Oncol Pract 2012;8:344-9
- (24) Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.** Chatelut et al., Br J Cancer 2012;107:1100-6
- (25) Characteristics of medication errors with parenteral cytotoxic drugs.** Fyhr et al., Eur J Cancer Care 2012;21:606-13
- (26) Analysis of the errors associated with the prescription, preparation and administration of cytostatic drugs.** Villar et al., Farm Hosp 2008;32:163-9
- (27) 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy.** Neuss et al., J Oncol Pract 2013;9:5s-13s
- (28) ISMP Safety Alert 21/10/2004. Lomustine** Accessible sur : <https://www.ismp.org/newsletters/acutecare/articles/A4Q04Action.asp>
- (29) ISMP Safety Alert 18/08/1998. Doxorubicine liposomale/conventionnelle.** Accessible sur : <http://www.ismp.org/hazardalerts/lipid.asp>
- (30) ISMP Safety Alert 07/02/2001. Paclitaxel/Docetaxel.** Accessible sur : <http://www.ismp.org/newsletters/acutecare/articles/20010207.asp>